Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Epithelial Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm

Cancer Family

Epithelial Neoplasm

CI-CAN-00000016Explore in graph →

Non-malignant7,525 active trials118 approved drugs1,152 evidence items

NCIt: C3709

Overview
Statistics
Survival
Genomics314
Variants & evidence1152
Drugs206
Trials26878
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (916)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 101–125 of 916 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.
· J Clin Oncol · 2013 · PMID 23182986 · validated civic_curation pubmed
FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis.
· Lung Cancer · 2015 · PMID 25433983 · validated civic_curation pubmed
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
· Ann Oncol · 2011 · PMID 21048039 · validated civic_curation pubmed
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
· Eur J Cancer · 2013 · PMID 23265711 · validated civic_curation pubmed
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
· Lancet Oncol · 2012 · PMID 22056021 · validated civic_curation pubmed
Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.
· Ann Oncol · 2014 · PMID 24799460 · validated civic_curation pubmed

Showing 101–125 of 916 publications

← Previous
1
…
4
5
6
…
37
Next →

Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.

· Cell Death Dis · 2014 · PMID 24577089 · validated civic_curation pubmed

Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.

· Onco Targets Ther · 2015 · PMID 26664143 · validated civic_curation pubmed

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

· PLoS One · 2015 · PMID 26086854 · validated civic_curation pubmed

Smoothened variants explain the majority of drug resistance in basal cell carcinoma.

· Cancer Cell · 2015 · PMID 25759020 · validated civic_curation pubmed

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.

· Oncotarget · 2017 · PMID 26625312 · validated civic_curation pubmed

Unique genomic profile of fibrolamellar hepatocellular carcinoma.

· Gastroenterology · 2015 · PMID 25557953 · validated civic_curation pubmed

ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.

· J Urol · 2015 · PMID 26162296 · validated civic_curation pubmed

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.

· EBioMedicine · 2015 · PMID 26137564 · validated civic_curation pubmed

Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis.

· J Transl Med · 2014 · PMID 25082261 · validated civic_curation pubmed

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

· J Clin Oncol · 2013 · PMID 23816960 · validated civic_curation pubmed

EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.

· Ann Oncol · 2011 · PMID 20826716 · validated civic_curation pubmed

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

· N Engl J Med · 2015 · PMID 25923549 · validated civic_curation pubmed

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

· Lancet Oncol · 2014 · PMID 24439929 · validated civic_curation pubmed

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

· Lancet Oncol · 2015 · PMID 25589191 · validated civic_curation pubmed

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

· Lancet Oncol · 2013 · PMID 23200175 · validated civic_curation pubmed

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

· J Clin Oncol · 2012 · PMID 22493419 · validated civic_curation pubmed

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

· Breast · 2015 · PMID 26255196 · validated civic_curation pubmed

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

· J Clin Oncol · 2010 · PMID 20124187 · validated civic_curation pubmed

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

· Lancet Oncol · 2016 · PMID 26822398 · validated civic_curation pubmed